Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 7/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13060027 | 1.00 | ABCB1 (0.48) | ABCB1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL13003212 | 1.00 | ABCB1 (0.48) | ABCB1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL3771854 | 1.00 | ABCB1 (0.48) | ABCB1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL8594670 | 0.90 | ABCB1 (0.51) | ABCB1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL3766544 | 0.90 | ABCB1 (0.51) | ABCB1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL14078518 | 0.89 | ABCB1 (0.50) | ABCB1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL13003218 | 0.89 | ABCB1 (0.45) | ABCB1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL16368763 | 0.89 | ABCB1 (0.45) | ABCB1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL15780071 | 0.89 | ABCB1 (0.45) | ABCB1CYP3A4 | |
| SCHEMBL8580401 | 0.88 | ABCB1 (0.49) | ABCB1CYP3A4CYP2C9CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9272986-B2 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150005256-A1 | Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes in Mammalian Systems via an Ecdysone Receptor Complex | INTREXON CORP (US) | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005256-A1 | Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes in Mammalian Systems via an Ecdysone Receptor Complex | NR2E3, NR2C2, NR5A2 | ABCB1 2844/4885CYP3A4 2962/4885CYP2C9 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.